突变型前尿激酶联合小剂量阿替普酶双溶栓治疗缺血性卒中的安全性与有效性:一项随机临床试验
这项在荷兰4个卒中中心开展的开放标签、盲法终点随机临床试验,纳入238例符合静脉溶栓指征但不适合血管内治疗的轻型缺血性卒中患者,比较5 mg阿替普酶团注联合40 mg突变型前尿激酶与标准0.9 mg/kg阿替普酶。结果显示两组24小时任何颅内出血发生率无显著差异(13.2% vs 13.7%),干预组纤维蛋白原未下降而对照组下降;双溶栓治疗并不优于单用阿替普酶。
要点
- 双溶栓组24小时任何颅内出血13.2%,对照组13.7%,调整OR 0.98(95%CI 0.46-2.12)。
- 双溶栓组症状性颅内出血0例,对照组3例(2.6%)。
- 双溶栓组1小时血浆纤维蛋白原保持稳定,对照组下降(β=65 mg/dL;95%CI 26-105 mg/dL)。
核心结论
- 在符合静脉溶栓指征但不适合血管内治疗的轻型缺血性卒中患者中,突变型前尿激酶双溶栓治疗不优于单用阿替普酶。
- 双溶栓治疗安全且未导致纤维蛋白原耗竭,但需在更大规模试验中进一步评估突变型前尿激酶溶栓治疗以改善较大面积缺血性卒中患者的结局。
研究设计与样本
- 这是一项对照、开放标签、盲法终点的随机临床试验,于2019年8月10日至2022年3月26日开展,总随访30天。
- 纳入荷兰4个卒中中心的成年缺血性卒中患者,按1:1随机分为干预组(5 mg静脉阿替普酶团注联合40 mg突变型前尿激酶静脉输注)和对照组(常规0.9 mg/kg静脉阿替普酶)。
- 共268例患者随机,238例提供延迟知情同意并纳入意向治疗人群(干预组121例,对照组117例;中位[IQR]年龄69[59-77]岁;男性147例[61.8%])。
- 基线美国国立卫生研究院卒中量表评分中位数为3分(IQR 2-5)。
- 主要结局为24小时神经影像学上的任何颅内出血;次要结局包括30天功能结局、症状性颅内出血和24小时内纤维蛋白原水平;分析按意向治疗进行,治疗效应经基线预后因素调整。
主要发现
- 任何颅内出血在干预组121例中发生16例(13.2%),对照组117例中发生16例(13.7%),调整比值比0.98(95%CI 0.46-2.12)。
- 突变型前尿激酶导致改良Rankin量表评分向更好方向非显著偏移(调整共同比值比1.16;95%CI 0.74-1.84)。
- 症状性颅内出血在干预组无患者发生,对照组117例中发生3例(2.6%)。
- 1小时血浆纤维蛋白原水平在干预组保持不变,而对照组下降(β=65 mg/dL;95%CI 26-105 mg/dL)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需在更大规模试验中进一步评估突变型前尿激酶溶栓治疗以改善较大面积缺血性卒中患者的结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Dual thrombolytic treatment with small bolus alteplase and mutant prourokinase has the potential to be a safer and more efficacious treatment for ischemic stroke than alteplase alone because mutant prourokinase is designed to act only on degraded fibrin without affecting circulating fibrinogen. OBJECTIVE: To assess the safety and efficacy of this dual thrombolytic treatment compared with alteplase. DESIGN, SETTING, AND PARTICIPANTS: This controlled, open-label randomized clinical trial with a blinded end point was conducted from August 10, 2019, to March 26, 2022, with a total follow-up of 30 days. Adult patients with ischemic stroke from 4 stroke centers in the Netherlands were enrolled. INTERVENTIONS: Patients were randomized (1:1) to receive a bolus of 5 mg of intravenous alteplase and 40 mg of an intravenous infusion of mutant prourokinase (intervention) or usual care with 0.9 mg/kg of intravenous alteplase (control). MAIN OUTCOMES AND MEASURES: The primary outcome was any intracranial hemorrhage (ICH) on neuroimaging at 24 hours. Secondary outcomes included functional outcome at 30 days, symptomatic ICH, and fibrinogen levels within 24 hours. Analyses were by intention to treat. Treatment effects were adjusted for baseline prognostic factors. RESULTS: A total of 268 patients were randomized, and 238 (median [IQR] age, 69 [59-77] years; 147 [61.8%] male) provided deferred consent and were included in the intention-to-treat population (121 in the intervention group and 117 in the control group). The median baseline score on the National Institutes of Health Stroke Scale was 3 (IQR, 2-5). Any ICH occurred in 16 of 121 patients (13.2%) in the intervention group and 16 of 117 patients (13.7%) in the control group (adjusted odds ratio, 0.98; 95% CI, 0.46-2.12). Mutant prourokinase led to a nonsignificant shift toward better modified Rankin Scale scores (adjusted common odds ratio, 1.16; 95% CI, 0.74-1.84). Symptomatic ICH occurred in none of the patients in the intervention group and 3 of 117 patients (2.6%) in the control group. Plasma fibrinogen levels at 1 hour remained constant in the intervention group but decreased in the control group (β = 65 mg/dL; 95% CI, 26-105 mg/dL). CONCLUSIONS AND RELEVANCE: In this trial, dual thrombolytic treatment with small bolus alteplase and mutant prourokinase was found to be safe and did not result in fibrinogen depletion. Further evaluation of thrombolytic treatment with mutant prourokinase in larger trials to improve outcomes in patients with larger ischemic strokes is needed. Overall, in patients with minor ischemic stroke who met indications for treatment with intravenous thrombolytics but were not eligible for treatment with endovascular therapy, dual thrombolytic therapy with intravenous mutant prourokinase was not superior to treatment with intravenous alteplase alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04256473.
引用
- van der Ende NAM, Roozenbeek B, Smagge LEM, et al. Safety and Efficacy of Dual Thrombolytic Therapy With Mutant Prourokinase and Small Bolus Alteplase for Ischemic Stroke: A Randomized Clinical Trial. JAMA Neurol. 2023. PMID: 37213122. doi:10.1001/jamaneurol.2023.1262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。